To perform a retrospective cohort study to determine the rates of recall and cancer detection and then to develop a decision analytic model to evaluate the effectiveness of routine screening of transverse rectus abdominis myocutaneous (TRAM) flap reconstructions.
Results:
Of 554 mammograms (265 TRAM flap reconstructions), 546 (98.6%) had negative results (Breast Imaging Reporting and Data System category 1 or 2). Eight (1.4%) had positive test results (Breast Imaging Reporting and Data System category 0, 3, 4, or 5). All suspicious lesions underwent biopsy and had benign pathologic results. No interval breast cancers were identified. The detection rate for nonpalpable recurrent breast cancer was 0% (exact 95% confidence interval: 0.0%, 1.4%). According to decision analysis, screening would help detect an estimated 12 additional recurrent cancers per 1000 women screened, providing an additional 1.6 days of life expectancy for the screened cohort. Under base-case conditions, screening of TRAM flap reconstructions is less effective than screening asymptomatic women in their 40s. Sensitivity analysis revealed that a benefit equivalent to that of screening asymptomatic women in their 40s was achievable under conditions related to estimates of screening effectiveness and cancer detection rate.
Conclusion:
Routine screening mammography of TRAM flap reconstructions has a very low detection rate for nonpalpable recurrent breast cancer. Decision analysis indicates that screening such women is less effective than screening asymptomatic women in their 40s for primary breast cancer.
F
or women undergoing mastectomy who choose reconstruction, options include an implant or autologous reconstruction. Of the autologous reconstruction methods, the transverse rectus abdominis myocutaneous (TRAM) flap is the most common. Although routine screening mammography of the TRAM flap breast reconstruction is not the current standard of care, the predominantly fatty composition of the reconstruction allows the performance of mammography. Previous reports have suggested that mammography in women with TRAM flap reconstructions after mastectomy can depict recurrence of nonpalpable breast cancer (1, 2) .
To better understand the potential benefit of mammographic screening of TRAM flap breast reconstructions, we performed a retrospective cohort study to determine the rates of recall and cancer detection after TRAM flap reconstruction surgery and then developed a decision analytic model to estimate the effectiveness of routine screening of TRAM flap reconstructions.
Materials and Methods
This study was supported in part by a GE-AUR Radiology Research Academic Fellowship, which is cosponsored by General Electric Healthcare Technologies and the Association of University Radiologists. The sponsors had no role in the design of the study, development of the model, or interpretation of results. The corresponding author had full control of the data and the information submitted for publication.
To evaluate the potential benefit of mammographic screening of TRAM flap breast reconstructions, we first performed a retrospective cohort study to determine the rates of recall and cancer detection associated with screening mammography of TRAM flap reconstructions at our institution. We then developed a decision analytic model to evaluate conditions under which routine screening of TRAM flap reconstructions might prove effective. This study was approved by our institutional review board, and its methods complied with Health Insurance Portability and Accountability Act regulations.
Cohort Study
Routine screening mammography of TRAM flap breast reconstructions has been performed at our institution since 1999. We retrospectively searched our institutional database of mammographic results to identify bilateral screening mammographic examinations obtained from January 1, 1999, through July 15, 2005, for which the report contained the term TRAM (database queried on July 29, 2005). Patients with non-TRAM autologous breast reconstructions were excluded. Diagnostic mammographic examinations performed for symptoms relating to the TRAM flap reconstruction were also excluded. The remaining 264 patients (265 TRAM flap reconstructions) who underwent mastectomy for treatment of primary breast cancer make up our study population (Tables 1, 2) .
The date and the prospective Breast Imaging Reporting and Data System (BI-RADS) (3) assessment determined for each mammogram were abstracted. Patient characteristics abstracted from the medical record included patient age at diagnosis of breast cancer, stage of breast cancer, dates of mastectomy and TRAM flap reconstruction, and duration of follow-up. Some patients underwent immediate reconstruction, whereas others underwent delayed reconstruction after mastectomy. We determined the duration of follow-up in this study from the date of mastectomy.
Screening mammograms with a BI-RADS assessment of category 1 or 2 were considered negative results. Screening mammograms with a BI-RADS assessment of 0, 3, 4, or 5 were considered positive results. All screening mammograms with a BI-RADS assessment of 0 were resolved into a final BI-RADS category ranging from 1 to 5. The recall rate was defined as the number of positive mammographic results out of the total number of mammograms obtained. The rate of detection of nonpalpable recurrent cancer was defined as the number of recurrent cancers diagnosed at screening mammography among the total number of patients in the study. We calculated the exact, binomial distribution-based 95% confidence interval (CI) around the cancer detection rate (Table 3) .
For all patients with positive screening mammograms, additional medical record review was done to determine clinical outcomes over the follow-up period. We also searched for false-negative screening mammographic results, 
Decision Analysis
We constructed a simple decision analytic model by using decision analysis software (TreeAge Pro 2007; TreeAge Software, Williamstown, Mass) to evaluate a hypothetical cohort of 55-yearold women who have undergone mastectomy and TRAM flap reconstruction for the treatment of breast cancer. Figure 1 presents the decision model structure. We compared two strategies: (a) usual care, in which physical examination by the patient and her physician is the primary means of detecting recurrent breast cancer (4) and (b) routine screening, in which recurrent breast cancer can be detected either with physical examination or a one-time mammographic screening examination 1 year after mastectomy. The model included the following parameters (Table 4) : the prevalence of recurrent breast cancer, the probability that the recurrent cancer was palpable or nonpalpable, the sensitivity and specificity of screening mammography, and the estimated effectiveness of screening in decreasing mortality from breast cancer. The base-case estimate of the prevalence of recurrent breast cancer in TRAM flap reconstructions was the mean value of estimates obtained from the medical literature (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . Because recurrences deep within the TRAM flap reconstruction are less likely to be palpable, the probability of having a nonpalpable recurrence was based on the observed proportion of deep versus superficial recurrences (5) . Because the sensitivity and specificity of screening mammography in TRAM flap reconstructions have not been reported, we used the test performance of screening mammography in American College of Radiology breast parenchymal pattern 1 breasts (almost entirely fatty) (15) as a proxy. A conservative estimate of the reduction in mortality from breast cancer in screening-detected recurrences in TRAM flap reconstructions (10%) was obtained after reviewing reports of screening mammographic trials (16, 17) . The rate of detection of nonpalpable recurrent breast cancer (1.2%) was calculated as the product of the prevalence of recurrent breast cancer, the probability of having a nonpalpable recurrence, and the sensitivity of mammography.
The outcome measure of the model is remaining life expectancy in the cohort of 55-year-old women who have undergone mastectomy and TRAM flap reconstruction. Because the primary outcome projected was absolute gain in life expectancy, no discounting or quality adjustments were made. The life expectancy for women with breast cancer recurrences was calculated by applying the Declining Exponential Approximation of Life Expectancy (DEALE) method (18) to mortality rates obtained from the published medical literature (5) . The median survival after superficial and deep recurrences in the reconstructed breast was used to approximate life expectancy after palpable and nonpalpable recurrences, respectively. The estimated life expectancy for 55-year-old women without breast cancer recurrence was obtained from U.S. life table data (19) . For the routine screening strategy, the life expectancy for women with a screening-detected nonpalpable recurrence was calculated by applying the DEALE method to the mortality rate for women with nonpalpable recurrent breast cancer, after adjustment by the estimated effectiveness of screening in decreasing breast cancer mortality.
Results

Retrospective Cohort
Our search identified 267 patients with 269 autologous breast reconstruction procedures. Three patients with non-TRAM flap reconstructions (two latissimus dorsi flaps and one free flap from the thigh) were excluded. In one patient who underwent mastectomy for treatment of breast cancer and prophylactic contralateral mastectomy with bilateral TRAM flap reconstructions, the TRAM flap reconstruction after prophylactic mastectomy was excluded. The remaining 264 patients (265 TRAM flap reconstructions) who underwent mastectomy for treatment of primary breast cancer make up our study population (Tables 1,  2) . A total of 554 screening mammographic examinations were performed in these patients. Among the 223 study patients for whom the date of reconstruction was known (84.5%), the median age at mastectomy was 48 (range, 32-71) years. The median duration of follow-up after mastectomy was 4.9 (range, 0.2-22.0) years.
Of the 554 screening mammograms obtained (Table 3) , 546 (98.6%) had negative results (BI-RADS category 1 or 2). Eight mammograms (1.4%) had positive results: BI-RADS category 0 (n ϭ 6), 3 (n ϭ 1), or 4 (n ϭ 1). These initial assessments were resolved into final assessments of BI-RADS category 2 (n ϭ 3), 3 (n ϭ 2), and 4 (n ϭ 3). All the BI-RADS category 4 lesions underwent excisional biopsy. A lesion described on the mammographic report as "solid hypoechoic mass versus complex cystic mass" was found to be a benign lymph node at pathologic examination. A cluster of suspicious microcalcifications (Fig 2) was found to be dense fibrosis with calcifications at pathologic examination. The third lesion for which biopsy was recommended was a cluster of suspicious microcalcifications. Pathologic examination revealed an organizing abscess within fibrous and adipose tissue with calcifications. Of the two patients 
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No interval nonpalpable recurrent breast cancers missed at mammography were identified. Thus, the rate of detection of nonpalpable recurrent cancer over the follow-up period was 0% (exact 95% CI: 0.0%, 1.4%).
Decision Analytic Model
The base-case estimate of the rate of detection of nonpalpable recurrent cancer was 1.2%, which is within the confidence intervals of both the results of our retrospective analysis and those of Helvie and colleagues' prior study of routine screening mammography of TRAM flap reconstructions (1) . Under the conditions of the base-case model, a strategy of routine screening would detect 12 additional recurrent cancers per 1000 women screened relative to the usual care strategy. The model indicates that a cohort of 55-year-old women undergoing routine screening after TRAM flap reconstruction would gain 1.6 days in life expectancy compared with usual care. This is less than the estimated life expectancy gain (2.5 days) from screening asymptomatic women in their 40s for primary breast cancer (20) .
Sensitivity analysis, summarized in Table 5 , revealed that a gain in life expectancy of 2.5 days was achievable under certain conditions, which were related to the following: (a) the estimate of screening effectiveness and (b) the rate of detection of nonpalpable recurrent cancer (Table 5) . With all other model parameters at their base-case values, a threshold breast cancer mortality benefit from screening of 15% was required for mammographic screening of TRAM flap reconstructions to be as beneficial as screening asymptomatic women in their 40s for primary breast cancer. At the base-case estimate of a 10% breast cancer mortality benefit with screening, the rate of detection of nonpalpable recurrent cancer would have to be 1.9% to achieve the same level of benefit. As the effect estimate of screening increased from 5% to 25%, the rate of detection of nonpalpable recurrent cancer necessary to achieve this effect decreased from 4.0% to 0.7%.
Discussion
With use of routine screening mammography, the rate of detection of recurrent nonpalpable cancer in TRAM flap breast reconstructions, over a median follow-up period of 4.9 years, was 0% (95% CI: 0.0%, 1.4%). To our knowledge, our retrospective study of routine mammographic screening of 265 TRAM flap reconstructions in 264 patients is the largest study reported to date. This very low rate contrasts with the findings in the study by Helvie et al (1) , who reported a 1.9% rate of detection of nonpalpable recurrent cancer (2 of 106 patients) with routine screening mammography.
The apparent difference in cancer detection rates between the two studies may be due to the large uncertainty about the true cancer detection rate associated with the small sample sizes in each study. The statistical power of screening studies, as with therapeutic studies, is based on the number of expected events. Because the population in a screening study is initially asymptomatic, a large number of patients would need to be screened to provide a precise estimate of the cancer detection rate. The 0% rate of detection of nonpalpable recurrent cancer in our 264 patients had an exact 95% CI of 0.0%, 1.4%, whereas Helvie et al (1) reported a 1.9% rate and a 95% CI of 0.2%, 6.7%. For our study to provide an estimate of the cancer detection rate that is statistically significantly different from that of Helvie et al, with nonoverlapping confidence intervals, we would need to have included approximately 10 times as many patients. That is, if we had studied 2640 patients, the same 0% rate of detection of nonpalpable recurrent cancer would have had a much narrower 95% CI of 0.0%, 0.1%.
Rates of breast cancer recurrence increase with advancing stage of the primary tumor (6) . Differences in the stage distribution of primary cancer in the study populations between our study and that of Helvie et al (1) may also contribute to the difference in reported cancer detection rates. In our study, nearly half the cancers (126 of 265, or 47.5%) were stage 0 (ductal carcinoma in situ) or stage I at diagnosis, and the very low recurrence rate we report is concordant with that. Also, because the mean time to breast cancer recurrence is less than 2 years (6), our inclusion of women who underwent mastectomy many years before the onset of routine screening excludes women whose breast cancer recurrences were diagnosed clinically in the first few years after mastectomy. Among study patients for whom the date of mastectomy is known, 102 of 226 women (45.1%) underwent mastectomy during or before 1997. This is at least 2 years before the onset of routine screening at our institution. These women may have been at very low risk of breast cancer recurrence.
Although the very low rate of detection of recurrent cancer we report suggests that routine screening of TRAM flap reconstructions may be unnecessary, its 95% CI includes the range of cancer detection rates reported with screening the general population of asymptomatic women (21) . We performed a simple decision analysis to integrate currently available information and to project the potential longer-term benefit of routine mammographic screening in TRAM flap reconstructions. We examined a strategy of onetime routine mammographic screening Although there is still insufficient evidence to recommend routine screening mammography for TRAM flap breast reconstructions, we described conditions under which its benefit approaches that of screening asymptomatic women in their 40s for primary breast cancer. As the estimated benefit of screening increased from a 5% to a 25% reduction in breast cancer mortality, the detection rate for nonpalpable recurrent cancer necessary to achieve the level of benefit gained from screening asymptomatic women in their 40s decreased from 4.0% to 0.7%.
While these conditions are plausibly met in the context of current clinical practice, the gain in life expectancy reported by Salzmann et al (20) from screening women in their 40s is based on a 16% reduction in breast cancer mortality reported in a meta-analysis of randomized controlled trials of mammographic screening conducted by Kerlikowske (25) . Several individual population-based randomized controlled trials of screening mammography (17, 26, 27) have reported greater reductions in breast cancer mortality as high as 44%. If a greater estimated reduction in breast cancer mortality from screening asymptomatic women in their 40s is assumed, then the current decision analysis would lead to an underestimate of the conditions under which the benefit from routine screening of TRAM flap reconstructions might reach that of screening asymptomatic women in their 40s. It is also important to note that the actual decrease in breast cancer mortality from routine screening of TRAM flap reconstructions and the actual rate of detection of nonpalpable recurrent breast cancer in TRAM flap reconstructions are not precisely known.
There are several limitations of our decision analysis. We modeled a onetime prevalence screen for a hypothetical cohort of 55-year-old women with primary breast cancer who have undergone mastectomy and TRAM flap breast reconstruction. Our base-case estimates of model parameters were based on the published medical literature and expert opinion. These results may change as new information on parameter values becomes available. The model structure does not provide information on the optimal timing of routine screening after mastectomy and reconstruction. In addition, it does not provide information on the optimal screening interval.
In summary, routine screening mammography of TRAM flap reconstructions is associated with a very low rate of detection of nonpalpable recurrent breast cancer. Decision analysis of the potential benefit from routine screening of TRAM flap reconstructions indicates that its effectiveness is less than that of screening asymptomatic women in their 40s for primary breast cancer.
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